CPIX
NASDAQCumberland Pharmaceuticals Inc.
Price$6.79-0.82 (-10.78%)
01:30 PM07:45 PM
News · 26 weeks51+14%
2026-01-182026-07-12
Mix2690d
- Other13(50%)
- SEC Filings9(35%)
- Dividends2(8%)
- Earnings1(4%)
- Offering1(4%)
Latest news
25 items- SECCumberland Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- PR/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc.//C O R R E C T I O N – Cumberland Pharmaceuticals Inc./ In the news release, CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE, issued July 13, 2026 by Cumberland Pharmaceuticals Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE Record Date is July 23, 2026 & Payment Date is July 31,2026Corporate and Insider Share Purchase Initiatives to ContinueNASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company deve
- PRCUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARERecord Date is July 10, 2026 & Payment Date is July 31,2026Corporate and Insider Share Purchase Initiatives to ContinueNASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026, to the shareholders of record at the close of business on July 10, 2026. Cumberland previously announced the closing of a Strategic Transaction with Apotex Health, resulting in the integration of the U.
- SECCumberland Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Other Events, Financial Statements and Exhibits8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- PRCumberland Pharmaceuticals Closes Strategic Transaction with Apotex$100 million Transaction Follows Cumberland Shareholder ApprovalStrengthens Cumberland's Focus on Rare Disease PipelineNASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses. Under the terms of the agreement, Apotex has acquired Cumberland's line of branded pharmaceuticals for cash consideration of $100 million funded at closing, which followed approval by Cumberland's shareholders. "We are pleased to complete this value-creating tran
- PRCumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual ConferenceAdditional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patientsNASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Orlando, Florida. The presentation highlighted key updates to the primary findings in the FIGHT DMD trial, reinforcing ifetroban's potential to address the leading c
- SECCumberland Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- PRRedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrantsTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the Company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an ag
- PRRedHill Biopharma Announces Up To $19.4 Million Private Placement$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrantsTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the Company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an aggregate of 8
- PRRedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug DesignationThe U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children--Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions --This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, FDA Prescription Drug User Fee Act (PDUFA) application fee waivers, tax credits and seven-years' marketing exclusivity, if approved--New preclinical data, presented at the 2026 American Association fo
- PRRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against KukboRALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has commenced recognition and enforcement proceedings in Korea in respect of the New York Supreme Court's final judgment in favor of RedHill against Kukbo Co. Ltd ("Kukbo"), totaling approximately $10.9 million, and that Kukbo has now been served in those proceedings. In November 2025, the New York Supreme Court judgment on the principal award became final and eligible for enforcement and foreign recognition. The award to RedHill of legal fees and expenses is now also final following Kukbo's failure
- PRCumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer MetastasisPositive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)Results support development of ifetroban as a candidate for metastasis preventionNASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors. Th
- PRRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense PlatformsAmid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib1, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platformOpaganib EVD rationale (analogous to EVD treatment pathway):Phase 3 clinical antiviral activity (severe COVID-19) showing2:70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median ti
- PRCUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINACommercialization in China through partnership with SciClone PharmaceuticalsExpands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical marketNASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited. The launch follows a previously announced agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product's approval by China's
- SECSEC Form DEFM14A filed by Cumberland Pharmaceuticals Inc.DEFM14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- SECSEC Form PREM14A filed by Cumberland Pharmaceuticals Inc.PREM14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- SECSEC Form 10-Q filed by Cumberland Pharmaceuticals Inc.10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- SECCumberland Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- PRRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseRHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD)In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048)3New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-1044. Importantly, MAP k
- PRCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATENASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically c
- PRRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights2025 was a year of tenacity, strategic transactions and building traction for RedHillTalicia® business transformed:Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partnership with Cumberland Pharmaceuticals ("Cumberland") (NASDAQ:CPIX), including Cumberland's $4 million investment for a 30% equity interest in THI planned to drive Talicia growth, and potentially additional revenue generating products. Cumberland and Apotex1, Canadian-based global health company, have since announced their planned strategic transaction to integrate Cumberland's U.S branded business into ApotexAdded eight million lives with coverage by Humana®'s Part D Plan and published new data supp
- SECCumberland Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- SECSEC Form DEFA14A filed by Cumberland Pharmaceuticals Inc.DEFA14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- SECCumberland Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
- PRCumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with ApotexTransaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical NeedsNASHVILLE, Tenn., April 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apotex"), the largest Canadian based pharmaceutical company to integrate their branded U.S. businesses. Under the terms of the agreement, Apotex will acquire Cumberland's line of branded pharmaceuticals for cash consideration of $100 million, and create a platform to deliver specialty medicines that improve the quality of patient care. The transaction is
CPIX FAQ
7 questionsWhat does Cumberland Pharmaceuticals Inc. do?
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol...Where does CPIX stock trade?
Cumberland Pharmaceuticals Inc. (CPIX) is listed on NASDAQ.What sector and industry is CPIX in?
Cumberland Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cumberland Pharmaceuticals Inc. go public?
Cumberland Pharmaceuticals Inc. (CPIX) completed its IPO in 2009.Does CPIX pay a dividend?
Yes. CPIX's next ex-dividend date is 2026-08-03 with a declared cash dividend of $1.50 per share, payable 2026-07-31.What companies are similar to CPIX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CPIX side-by-side with any of them on Quantisnow.How can I track CPIX on Quantisnow?
Quantisnow aggregates Cumberland Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CPIX to receive live email and push alerts on every new disclosure.